Strides Arcolab receives US FDA approval for its facility

Mumbai, May 25 (UNI) Pharma major Strides Arcolab today said it has secured the approval of the US Food and Drug Administration (FDA) for its sterile manufacturing site in Bangalore and has been classified as acceptable for manufacturing sterile products for the US market.

''The US FDA approval of the sterile facility in Bangalore is an important milestone for the Company's US strategy, as this Pre-Approval Inspection (PAI) will support the product submissions for sterile injectables with the FDA,'' Strides Vice Chairman and Managing Director Arun Kumar said.

UNI